Griseofulvin compound

ABSTRACT

wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

TECHNICAL FIELD

The present invention relates to a compound having a specific chemicalstructure having an anti-inflammatory activity or a pharmacologicallyacceptable salt thereof.

BACKGROUND ART

Griseofulvin is an antibiotic substance isolated for the first time byAE Oxford et al., from one of Penicillium belonging to Aspergillusoryzae, i.e., Penicillium griseofulvum (Non patent Reference 1) in 1939.Griseofulvin is mainly administered orally. However, it is a lesssoluble and readily absorbable medicinal substance and thus complicatedin its oral absorption kinetics. Griseofulvin is used as an antifungaldrug against dermatophytes such as Microsporum, Trichophyton andEpidermophyton (Non patent References 2, 3).

Griseofulvin binds to tubulin within a cell to thereby terminate thecell cycle at the G2/M period and induce abnormality in mitoticdivision, with the result that growth of various cells of, e.g., fungi,plants and mammals is suppressed. Compared to mammalian cells, fungalcells are suppressed in growth at an extremely low concentration ofgriseofulvin. This is considered to be because the binding affinity ofgriseofulvin for fungus tubulin is higher than for mammalian tubulin.Griseofulvin also binds to microtubule-associated proteins (MAPs) tosuppress dynamic instability of microtubules, thereby stabilizingmicrotubule movement (Non patent Reference 4).

Griseofulvin has a growth suppression action on human cancer cells andan activity which induces apoptosis thereof. Griseofulvin, if it isapplied to a tumor transplanted in an athymic nude mouse in combinationwith nocodazole, exhibits antitumor activity. From this, griseofulvin isexpected to have effectiveness as an anti-cancer agent (Non patentReference 5).

In the meantime, it has long been known that griseofulvin has ananti-inflammatory activity other than the antifungal action. Forexample, it was found that griseofulvin exhibits anti-inflammatoryactivity on rat inflammation models with formalin edema and cottonpellet granuloma (Non patent Reference 6). In clinical practice, it isreported that griseofulvin has a medicinal effect on nonfungalinflammatory skin diseases such as lichen planus (Non patent Reference7), plasma cell cheilitis (Non patent Reference 8) and pigmentedpurpuric dermatosis (Non patent Reference 9).

It is also reported that griseofulvin has a medicinal effect on, e.g.,livedoid vasculitis (Non patent Reference 9), polyarthritis such asshoulder-hand syndrome and scapulo-humeral periarthritis (Non patentReferences 6, 10).

It is found that griseofulvin has an action on the microtubules ofleucocytes and an antagonistic action, in vitro, on chemical mediatorsof inflammation such as histamine, serotonin and prostaglandin (Nonpatent Reference 6). However, the specific mechanism of griseofulvinaction in anti-inflammation has not yet been elucidated.

Likewise, griseofulvin has various physiological activities and, untilnow, various derivatives of griseofulvin have been synthesized throughreplacement of substituents (Non patent Reference 11).

CITATION LIST Non Patent References

-   Non patent Reference 1: Oxford AE, Raistrick H, Simonart P. Studies    in the biochemistry of micro-organisms: Griseofulvin, C (17)H (17)O    (6)Cl, a metabolic product of Penicillium griseo-fulvum Dierckx.    Biochem J. 1939 February; 33 (2): 240-8-   Non patent Reference 2: Gentles J C. Experimental ringworm in guinea    pigs: oral treatment with griseofulvin. Nature. 1958 Aug. 16; 182    (4633): 476-7-   Non patent Reference 3: Williams D I, Marten R H, Sarkany I. Oral    treatment of ringworm with griseofulvin. Lancet. 1958 Dec. 6; 2    (7058): 1212-3 Non patent Reference 4: Wehland J, Herzog W, Weber K.    Interaction of griseofulvin with microtubules, microtubule protein    and tubulin. J Mol Biol. 1977 Apr. 15; 111 (3): 329-42-   Non patent Reference 5: Ho Y S, Duh J S, Jeng J H, Wang Y J, Liang Y    C, Lin C H, Tseng C J, Yu C F, Chen R J, Lin J K. Griseofulvin    potentiates antitumorigenesis effects of nocodazole through    induction of apoptosis and G2/M cell cycle arrest in human    colorectal cancer cells. Int J Cancer. 2001 Feb. 1; 91 (3): 393-401-   Non patent Reference 6: Sorrentino L, Capasso F, Di Rosa M.    Anti-inflammatory properties of griseofulvin. Agents Actions. 1977    March; 7 (1): 157-62-   Non patent Reference 7: Sehgal V N, Bikhchandani R, Koranne R V,    Nayar M, Saxena H M. Histopathological evaluation of griseofulvin    therapy in lichen planus. A double-blind controlled study.    Dermatologica. 1980; 161 (1): 22-7-   Non patent Reference 8: Tamaki K, Osada A, Tsukamoto K, Ohtake N,    Furue M. Treatment of plasma cell cheilitis with griseofulvin. J Am    Acad Dermatol. 1994 May; 30 (5 Pt 1): 789-90-   Non patent Reference 9: Tamaki K, Yasaka N, Osada A, Shibagaki N,    Furue M. Successful treatment of pigmented purpuric dermatosis with    griseofulvin. Br J Dermatol. 1995, January; 132 (1): 159-60-   Non patent Reference 10: Cohen A, Goldman J, Daniels R, Kanenson W.    Treatment of shoulder-hand syndrome with griseofulvin. J Am Med    Assoc. 1960 Jun. 4; 173: 542-3-   Non patent Reference 11: Petersen A B, Ronnest M H, Larsen, T O,    Clausen M H. The Chemistry of Griseofulvin. Chem. Rev. 2014    December; 114: 12088-12107

SUMMARY OF INVENTION Technical Problem

The present invention provides a compound having a specific chemicalstructure having an anti-inflammatory activity which is useful as anactive ingredient for preventing and treating an inflammatory disease, apharmacologically acceptable salt thereof or the like, a novelproduction method therefor and an intermediate. Since the compound ofthe present invention or a pharmacologically acceptable salt thereof hasdifferent properties, in various aspects, from those of knownanti-inflammatory drugs, the compound or a salt thereof is considered tobe useful as a novel medicine.

Solution to Problem

The present inventors conducted intensive studies for developing acompound which is useful as an active ingredient for preventing andtreating an inflammatory disease, a pharmacologically acceptable saltthereof or the like. As a result, they found the compound of the presentinvention, a pharmacologically acceptable salt thereof or the like. Morespecifically, the present invention is as described below.

A compound of general formula (1) or a pharmacologically acceptable saltthereof.

wherein the symbols in the formula are defined below:

R¹: a C1-C6 alkyl group or a hydroxyC1-C6 alkyl group,

R²: a C1-C6 alkyl group,

A: a 5-membered aromatic heterocycle having bonds and having 1-4 atomsselected from the group consisting of a nitrogen atom, an oxygen atomand a sulfur atom; or an oxygen atom, and

R³: if A is a 5-membered aromatic heterocycle having bonds and having1-4 atoms selected from the group consisting of a nitrogen atom, anoxygen atom and a sulfur atom, then R³ is a C1-C6 alkyl group, ahydroxyC1-C6 alkyl group or a C1-C6 alkoxyC1-C6 alkyl group; and if A isan oxygen atom, then R³ is a hydroxyC1-C6 alkyl group or a C1-C6alkoxyC1-C6 alkyl group.

A compound or a pharmacologically acceptable salt thereof according to[1], wherein R¹ is a methyl group, an ethyl group or a hydroxyethylgroup.

A compound or a pharmacologically acceptable salt thereof according to[1] or [2], wherein R² is a methyl group.

A compound or a pharmacologically acceptable salt thereof according toany one of [1] to [3], wherein A is a 5-membered aromatic heterocyclehaving bonds and having 1-4 atoms selected from the group consisting ofa nitrogen atom, an oxygen atom and a sulfur atom; and R³ is a methylgroup, an ethyl group, a hydroxyC1-C3 alkyl group or a methoxyC1-C3alkyl group.

A compound or a pharmacologically acceptable salt thereof according toany one of [1] to [4], wherein A is a 5-membered aromatic heterocyclehaving bonds selected from the following group:

wherein * represents a bond.

A compound or a pharmacologically acceptable salt thereof according toany one of [1] to [3], in which A is an oxygen atom.

A compound of general formula (1) or a pharmacologically acceptable saltthereof.

wherein the symbols in the formula are defined below:

R¹: a methyl group, an ethyl group or a hydroxyethyl group,

R²: a methyl group,

A: a 5-membered aromatic heterocycle having bonds and selected from thefollowing group:

wherein * represents a bond,

R³: a methyl group, an ethyl group or a hydroxyC1-C3 alkyl group.

A compound or a pharmacologically acceptable salt thereof selected fromthe following group:

-   (2S,5′R)-7-chloro-6-(2-hydroxyethoxy)-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-3′,4-dimethoxy-6-(2-methoxyethoxy)-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(1-methylpyrazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-6-(1-ethylpyrazol-3-yl)-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-6-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-4-ethoxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-4-ethoxy-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-6-[3-(1-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3′,4-dimethoxy-5′-methyl-spiro    [benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione,-   (2S,5′R)-7-chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)    spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione, and-   (2S,5′R)-7-chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione.

A pharmaceutical composition containing a compound or apharmacologically acceptable salt thereof according to any one of [1] to[8] as an active ingredient.

A pharmaceutical composition according to [9], for preventing and/ortreating an inflammatory disease.

A pharmaceutical composition according to [10], wherein the inflammatorydisease is a disease selected from the group consisting of rheumatoidarthritis, systemic lupus erythematosus, scleroderma, bronchial asthma,asthmatic bronchitis, diffuse interstitial pneumonia, chronicobstructive pulmonary disease, ulcerative colitis, Crohn's disease,acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmunehepatitis, primary biliary cirrhosis, primary sclerosing cholangitis,alcoholic hepatitis, non-alcoholic steatohepatitis, cirrhosis,peripheral neuritis, ankylosing spondylitis, eczema (acute, subacute,chronic), contact dermatitis, sunlight (ultraviolet light) dermatitis,radiation dermatitis, atopic dermatitis, seborrheic dermatitis,psoriasis vulgaris, arthropathic psoriasis, psoriatic erythroderma,pustular psoriasis, lichen planus, erythema, rosacea, urticaria,alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure sore,wound, burn, conjunctivitis, keratitis, scleritis, acute/chronic otitismedia, perennial allergic rhinitis, hay fever, sinusitis, laryngitis,esophagitis, refractory stomatitis, glossitis, acute/chronic salivarygland inflammation, angular cheilitis, cheilitis, Behcet's disease,multiple sclerosis, Type I diabetes, Type II diabetes, atherosclerosis,pancreatitis and chronic heart failure.

A pharmaceutical composition according to [10], wherein the inflammatorydisease is a disease selected from the group consisting of rheumatoidarthritis, systemic lupus erythematosus, bronchial asthma, acutehepatitis, autoimmune hepatitis, primary biliary cirrhosis, primarysclerosing cholangitis, alcoholic hepatitis, nonalcoholicsteatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight(UV) dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasisvulgaris, arthropathic psoriasis, psoriatic erythroderma, pustularpsoriasis, lichen planus, erythema, rosacea, alopecia areata, pemphigus,erythroderma, acne vulgaris, pressure sore, wound, burn, sinusitis,laryngitis, esophagitis, refractory stomatitis, glossitis, acute/chronicsalivary gland inflammation, angular cheilitis, cheilitis and Behcet'sdisease.

A pharmaceutical composition according to [10], wherein the inflammatorydisease is a disease selected from the group consisting of rheumatoidarthritis, systemic lupus erythematosus, autoimmune hepatitis, alcoholichepatitis, nonalcoholic steatohepatitis, ankylosing spondylitis, atopicdermatitis, psoriasis vulgaris, arthropathic psoriasis, psoriaticerythroderma, pustular psoriasis, lichen planus, pressure sore, wound,refractory stomatitis, glossitis and Behcet's disease.

A compound or a pharmacologically acceptable salt thereof according toany one of [1] to [8] for treating an inflammatory disease.

A method for administering an effective amount of a pharmaceuticalcomposition according to [9] for preventing and/or treating aninflammatory disease.

A TNF-α inhibitor containing a compound or a pharmacologicallyacceptable salt thereof according to any one of [1] to [8], as an activeingredient.

Advantageous Effects of the Invention

The compound of the present invention, a pharmacologically acceptablesalt thereof or the like is useful as an active ingredient forpreventing and/or treating an inflammatory disease. Examples of theinflammatory disease include rheumatoid arthritis, systemic lupuserythematosus, scleroderma, bronchial asthma, asthmatic bronchitis,diffuse interstitial pneumonia, chronic obstructive pulmonary disease,ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis,fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis,primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholicsteatohepatitis, cirrhosis, peripheral neuritis, ankylosing spondylitis,eczema (acute, subacute, chronic), contact dermatitis, sunlight(ultraviolet light) dermatitis, radiation dermatitis, atopic dermatitis,seborrheic dermatitis, psoriasis vulgaris, arthropathic psoriasis,psoriatic erythroderma, pustular psoriasis, lichen planus, erythema,rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acnevulgaris, pressure sore, wound, burn, conjunctivitis, keratitis,scleritis, acute/chronic otitis media, perennial allergic rhinitis, hayfever, sinusitis, laryngitis, esophagitis, refractory stomatitis,glossitis, acute/chronic salivary gland inflammation, angular cheilitis,cheilitis, Behcet's disease, multiple sclerosis, Type I diabetes, TypeII diabetes, atherosclerosis, pancreatitis and chronic heart failure.

Preferred examples thereof include rheumatoid arthritis, systemic lupuserythematosus, bronchial asthma, acute hepatitis, autoimmune hepatitis,primary biliary cirrhosis, primary sclerosing cholangitis, alcoholichepatitis, nonalcoholic steatohepatitis, ankylosing spondylitis, contactdermatitis, sunlight (UV) dermatitis, atopic dermatitis, seborrheicdermatitis, psoriasis vulgaris, arthropathic psoriasis, psoriaticerythroderma, pustular psoriasis, lichen planus, erythema, rosacea,alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure sore,wound, burn, sinusitis, laryngitis, esophagitis, refractory stomatitis,glossitis, acute/chronic salivary gland inflammation, angular cheilitis,cheilitis and Behcet's disease.

More preferred examples thereof include rheumatoid arthritis, systemiclupus erythematosus, autoimmune hepatitis, alcoholic hepatitis,nonalcoholic steatohepatitis, ankylosing spondylitis, atopic dermatitis,psoriasis vulgaris, arthropathic psoriasis, psoriatic erythroderma,pustular psoriasis, lichen planus, pressure sore, wound, refractorystomatitis, glossitis and Behcet's disease.

The present invention provides a novel and efficient method forproducing the compound of the present invention or the like, and anintermediate. Accordingly, the present invention is advantageous inproducing a medicinal drug.

DESCRIPTION OF EMBODIMENTS

Now, the present invention will be more specifically described below.

(Explanation of Substituents and Terms)

The present invention is directed to a compound of general formula (1)or a pharmacologically acceptable salt thereof.

wherein the symbols in the formula are defined below:

R¹: a C1-C6 alkyl group or a hydroxyC1-C6 alkyl group,

R²: a C1-C6 alkyl group,

A: a 5-membered aromatic heterocycle having bonds and having 1-4 atomsselected from the group consisting of a nitrogen atom, an oxygen atomand a sulfur atom, or an oxygen atom,

R³: if A is a 5-membered aromatic heterocycle having bonds and having1-4 atoms selected from the group consisting of a nitrogen atom, anoxygen atom and a sulfur atom, then R³ is a C1-C6 alkyl group, ahydroxyC1-C6 alkyl group or a C1-C6 alkoxyC1-C6 alkyl group; and if A isan oxygen atom, then R³ is a hydroxyC1-C6 alkyl group or a C1-C6alkoxyC1-C6 alkyl group.

The C1-C6 alkyl group represented by R¹ is a linear or branched alkylgroup having 1-6 carbon atoms and preferably a methyl group or an ethylgroup.

The hydroxyC1-C6 alkyl group represented by R¹ is a linear or branchedalkyl group having 1-6 carbon atoms substituted by a hydroxy group andpreferably a hydroxyethyl group.

The C1-C6 alkyl group represented by R² is a linear or branched alkylgroup having 1-6 carbon atoms and preferably a methyl group.

The C1-C6 alkyl group represented by R³ is a linear or branched alkylgroup having 1-6 carbon atoms and preferably a methyl or ethyl group.

The hydroxyC1-C6 alkyl group represented by R³ is a linear or branchedalkyl group having 1-6 carbon atoms substituted by a hydroxy group andpreferably a hydroxyC1-C3 alkyl group. Examples thereof include ahydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a1-hydroxy-1-methyl-ethyl group, a 1-hydroxypropyl group and a2-hydroxypropyl group.

The C1-C6 alkoxyC1-C6 alkyl group represented by R³ is a linear orbranched alkyl group having 1-6 carbon atoms substituted by a C1-C6alkoxy group and preferably a methoxyC1-C3 alkyl group. Examples thereofinclude a methoxymethyl group, a 1-methoxyethyl group, a 2-methoxyethylgroup, a 1-methoxypropyl group and a 2-methoxypropyl group.

The 5-membered aromatic heterocycle represented by A is a 5-memberedaromatic heterocycle containing 1-4 atoms selected from the groupconsisting of a nitrogen atom, an oxygen atom and a sulfur atom, andhaving two bonds. Examples thereof include the following 5-memberedaromatic heterocycles:

pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole,furan, isoxazole, oxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole,1,2,5-oxadiazole, thiophene, thiazole, isothiazole, 1,2,4-thiadiazole,1,3,4-thiadiazole and 1,2,5-thiadiazole.

It is further preferred that the following 5 member rings are included.

wherein * represents a bond.

The 5-membered aromatic heterocycles respectively form the followingcompounds serving as a compound of general formula (1), via the bonds.

wherein R¹, R² and R³ are as defined above.

The term “pharmacologically acceptable salt thereof” refers to a saltwhich can be used as a medicinal drug. In the case of a compound havingan acidic group or a basic group, a basic salt or an acid salt can beproduced if a base or an acid is reacted with the group. The salt thusobtained represents a pharmacologically acceptable salt.

Examples of a pharmacologically acceptable “basic salt” of a compoundpreferably include an alkali metal salt such as a sodium salt, apotassium salt and a lithium salt; an alkaline earth metal salt such asa magnesium salt and a calcium salt; an organic base salt such as aN-methyl morpholine salt, a triethylamine salt, a tributylamine salt, adiisopropylethylamine salt, a dicyclohexylamine salt, a N-methylpiperidine salt, a pyridine salt, a 4-pyrrolidinopyridine salt and apicoline salt; and an amino acid salt such as a glycine salt, a lysinesalt, an arginine salt, an ornithine salt, glutamate and aspartate.Preferably, an alkali metal salt is mentioned.

Preferred examples of a pharmacologically acceptable “acid salt” of acompound include inorganic acid salts including a hydrohalic acid saltsuch as a hydrofluoride, a hydrochloride, a hydrobromide and ahydriodide, a nitrate, a perchlorate, a sulfate and a phosphate; organicacid salts including a lower alkanesulfonate such as a methanesulfonate,a trifluoromethanesulfonate and an ethanesulfonate, an aryl sulfonatesuch as a benzenesulfonate and p-toluene sulfonate, an acetate, amalate, a fumarate, a succinate, a citrate, an ascorbate, a tartrate, anoxalate and a maleate; and amino acid salts such as a glycine salt, alysine salt, an arginine salt, an ornithine salt, a glutamate and anaspartate. Most preferably, a hydrohalic acid salt (particularly,hydrochloride) is mentioned.

The compound of the present invention or a pharmacologically acceptablesalt thereof sometimes absorbs water or adsorbs moisture or forms ahydrate when it is left alone in the air or by re-crystallization. Thesevarious hydrates, solvates and polymorphic compounds are also includedin the present invention.

The compound of the present invention, a pharmacologically acceptablesalt thereof or a solvate thereof may have various type of isomersincluding geometric isomers such as a cis isomer and a trans isomer,tautomers, and optical isomers such as d-form and 1-form depending onthe types and combinations of substituents. However, unless otherwisespecified, all isomers, stereoisomers and a mixture of these isomers andstereoisomers in any mixing ratio are included in the compound of thepresent invention. A mixture of these isomers can be separated by aseparation means known in the art.

As the compound of the present invention, a labeled compound, morespecifically, a compound having 1 or 2 or more atoms substituted with anisotope (for example, 2H, 3H, 13C, 14C, 35S), is also included.

In the present invention, a so-called prodrug is also included. The termprodrug refers to a compound having a group that can be converted intoan amino group, a hydroxyl group or a carboxyl group by hydrolysis or inphysiological conditions. The groups involved in forming such prodrugsare described in Prog. Med., vol. 5, 2157-2161 pages, 1985. Morespecifically, the prodrug can be as mentioned below.

If an amino group is present, e.g., a compound having an acylated,alkylated or phosphorylated amino group (for example, a compound havingan eicosanoylated, alanylated, pentylaminocarbonylated,(5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonylated,tetrahydrofuranylated, pyrrolidyl methylated, pivaloyloxymethylated or atert-butylated amino group) can be mentioned.

If a hydroxyl group is present, e.g., a compound having an acylated,alkylated, phosphorylated or borated hydroxyl group (for example, acompound having an acetylated, palmitoylated, propanoylated,pivaloylated, succinylated, fumarylated, alanylated ordimethylaminomethylcarbonylated hydroxyl group) can be mentioned.

If a carboxy group is present, e.g., a compound having an esterified oramidated carboxy group (for example, a compound having anethyl-esterified, phenyl-esterified, carboxymethyl-esterified,dimethylaminomethyl-esterified, pivaloyloxymethyl-esterified,ethoxycarbonyloxyethyl-esterified, amidated or methylamidated carboxygroup) can be mentioned.

(Production Method)

Now, the production method will be described. However, a method forproducing a compound or a salt thereof is not limited by the methodsdescribed below.

[Method A]

Method A is a method of producing a compound (A-III) of the presentinvention

wherein R¹, R² and R³ are the same as defined above; and X represents aleaving group such as a halogen group.

(Step A1) Demethylation Step

This is a step of obtaining a compound (A-II) from a compound (A-I) byuse of a metal halide in the presence of a base and crown ether.

Examples of the base include triethylamine, diisopropylethylamine andpyridine.

Examples of the crown ether include 18-crown-6.

Examples of the metal halide include potassium iodide.

As a solvent, e.g., N,N-dimethylformamide may be mentioned or a solventmay not be used. The reaction temperature is usually about 60 to 120° C.and the reaction time is usually about 1 to 24 hours.

(Step A2) Alkylation Step

(Case of Using Alkyl Halide)

This is a step of obtaining a compound (A-III) from a compound (A-II) byuse of the corresponding alkylating reagent in the presence of a base.

Examples of the alkylating reagent include an alkyl halide such as analkyl iodide and an alkyl bromide and a sulfonic acid ester such as analkyl tosylate and an alkyl mesylate.

Examples of the base include triethylamine, diisopropylethylamine, andpotassium carbonate.

As a solvent, tetrahydrofuran, 1,4-dioxane, acetonitrile,dichloromethane and N,N-dimethylformamide or a mixture of these can bementioned. The reaction temperature is usually about 0 to 100° C. andthe reaction time is usually about 0.5 to 24 hours.

(Case of Using the Mitsunobu Reaction)

This is a step of obtaining a compound (A-III) from a compound (A-II) byuse of the corresponding alcohol in the presence of a phosphine and anazodicarboxylate or a diazodicarboxamide.

Examples of the phosphine include triphenylphosphine andtri-n-butylphosphine.

Examples of the azodicarboxylate or diazodicarboxamide include diethylazodicarboxylate, di-tert-butyl azodicarboxylate and1,1′-(azodicarbonyl) dipyridine.

As a solvent, tetrahydrofuran, 1,4-dioxane, toluene or a mixture ofthese can be mentioned. The reaction temperature is usually about 0 to100° C. and the reaction time is usually about 0.5 to 24 hours.

[Method B]

Method B is a method of producing a compound (B-III) (equivalent to thecompound (A-I) that is used in Method A). If R¹ is a methyl group, acompound (B-III) can be produced without employing these steps.

wherein R¹, R² and X are the same as defined above.

(Step B1) Demethylation Step

This is a step of obtaining a compound (B-II) from a compound (B-I) byuse of a metal halide.

Examples of the metal halide include magnesium iodide.

As a solvent, toluene, tetrahydrofuran, 1,4-dioxane or a mixture ofthese can be mentioned.

The reaction temperature is usually about 60 to 120° C. and the reactiontime is usually about 0.5 to 24 hours.

(Step B2) Phenol Alkylation Step

This is a step of obtaining a compound (B-III) from a compound (B-II) inthe same manner as in (Step A2).

[Method C]

Method C is a method of producing a compound (C-III) of the presentinvention from compound (C-I) (equivalent to compound (A-II) that isused in Method A).

wherein R¹, R², R³ and A are the same as defined above; Tf represents atrifluoromethanesulfonyl group; and B* represents a borono group(—B(OH)₂) or a 4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl group.

(Step C1) Trifluoromethanesulfonylation Step

This is a step of obtaining a compound (C-II) from a compound (C-I) byuse of a trifluoromethanesulfonylating reagent in the presence of abase.

Examples of the trifluoromethanesulfonylation reagent includetrifluoromethanesulfonic anhydride, trifluoromethanesulfonic chlorideand N-phenylbis(trifluoromethanesulfonimide).

Examples of the base include triethylamine and diisopropylethylamine.

As a solvent, tetrahydrofuran, 1,4-dioxane, acetonitrile,dichloromethane or a mixture of these can be mentioned.

The reaction temperature is usually, −20° C. to about room temperatureand the reaction time is usually about 0.5 to 24 hours.

(Step C2) Step of Coupling Reaction Using Transition Metal Catalyst

This is a step of obtaining a compound (C-III) from a compound (C-II) byuse of a palladium catalyst and R³-A-B* in the presence of a base.

Examples of the palladium catalyst include tetrakis(triphenylphosphine)palladium, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, tris(dibenzylideneacetone)dipalladium, palladiumacetate, acetylacetone palladium and bis(triphenylphosphine)palladiumdichloride.

Examples of the base include triethylamine, diisopropylethylamine,1,8-diazabicyclo[5.4.0]-7-undecene (DBU),1,5-diazabicyclo[4.3.0]-5-nonen (DBN), potassium hydrogen carbonate,sodium hydrogen carbonate, potassium carbonate, sodium carbonate,potassium hydroxide, sodium hydroxide, potassium phosphate and sodiumphosphate.

As a solvent, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, water,N,N-dimethylformamide, dimethylsulfoxide, toluene or a mixture of thesecan be mentioned.

The reaction temperature is usually about 60 to 120° C. and the reactiontime is usually about 0.5 to 12 hours.

[Method D]

Method D is a method of producing a compound (D-IV) of the presentinvention from a compound (D-I) (equivalent to the compound (C-II) thatis used in Method C).

wherein R¹, R², R³ and Tf are the same as defined above and R⁴represents a phenyl group that may have a substituent.

(Step D1) Step of Coupling with Formate

This is a step of obtaining a compound (D-II) from a compound (D-I) byuse of a formate in the presence of a base and a palladium catalyst(phosphine ligand).

Examples of the base include triethylamine, diisopropylethylamine,dimethylaminopyridine, potassium carbonate, sodium carbonate, potassiumhydroxide and sodium hydroxide.

Examples of the formate include phenyl formate and(2,4,6-trichlorophenyl) formate.

Examples of the palladium catalyst include palladium acetate,acetylacetone palladium, palladium trifluoroacetate, palladiumdichloride, tris(dibenzylideneacetone)dipalladium orbis(triphenylphosphine)palladium dichloride.

Examples of the phosphine ligand to be used simultaneously with thepalladium catalyst include4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantphos),1,1′-bis(diphenylphosphino)ferrocene (dppf),2,2′-bis(diphenylphosphino)-1,1-binaphthyl (BINAP),bis(diphenylphosphino)methane (DPPM), triphenylphosphine and1,2-bis(diphenylphosphino)ethane (DPPE).

As a solvent, N,N-dimethylformamide, toluene, tetrahydrofuran,acetonitrile or a mixture of these can be mentioned.

The reaction temperature is usually about room temperature to 120° C.and the reaction time is usually about 1 to 8 hours.

(D2 Step) Step of Amidation with Acyl Hydrazine

This is a step of obtaining a compound (D-III) from a compound (D-II) byuse of the corresponding acyl hydrazine in the presence of a base.

Examples of the base include triethylamine, diisopropylethylamine,dimethylaminopyridine, potassium carbonate, sodium carbonate, potassiumhydroxide and sodium hydroxide. An additive such as N-hydroxysuccinimide(HOSu), 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole(HOAt) is sometimes advantageously used in order to make the reactionprogress smoothly.

As a solvent, N,N-dimethylformamide, dichloromethane, tetrahydrofuran,acetonitrile or a mixture of these can be mentioned.

The reaction temperature is usually about 0 to 60° C. and the reactiontime is usually about 1 to 12 hours.

(Step D3) Cyclization Step

This is a step of obtaining a compound (D-IV) from a compound (D-III) byuse of a dehydrating agent.

Examples of the dehydrating agent include(methoxycarbonylsulfamoyl)triethylammonium hydroxide inner salt,phosphoryl chloride, polyphosphoric acid, sulfuric acid,triphenylphosphine/iodine, tosylate and tosyl chloride.

As a solvent, toluene, acetonitrile, dichloromethane or a mixture ofthese solvents can be mentioned. A solvent may not be used.

The reaction temperature is usually about 0 to 100° C. and the reactiontime is usually about 0.5 to 24 hours.

[Method E]

Method E is a method of producing a compound (E-III) of the presentinvention from a compound (E-I) (equivalent to the compound (D-II) thatis used in Method D).

wherein R¹, R², R³ and R⁴ are the same as defined above.

(Step E1) Step of Acylation with Amidoxime

This is a step of obtaining a compound (E-II) from a compound (E-I) byuse of the corresponding amidoxime in the presence of a base.

Examples of the base include triethylamine, diisopropylethylamine,dimethylaminopyridine, potassium carbonate, sodium carbonate, potassiumhydroxide and sodium hydroxide. An additive such as N-hydroxysuccinimide(HOSu), 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole(HOAt) is sometimes advantageously used in order to make the reactionprogress smoothly.

As a solvent, N,N-dimethylformamide, dichloromethane, tetrahydrofuran,acetonitrile or a mixture of these can be mentioned.

The reaction temperature is usually about room temperature to 80° C. andthe reaction time is usually about 1 to 12 hours.

(Step E2) Cyclization Step

This is a step of obtaining a compound (E-III) by stirring a compound(E-II) in a solvent at room temperature or under heating.

As the solvent, toluene, N,N-dimethylformamide, dichloromethane,tetrahydrofuran, acetonitrile or a mixture of these can be mentioned.

The reaction temperature is usually about room temperature to 100° C.and the reaction time is usually about 0.5 to 24 hours.

[Method F]

Method F is a method of producing a compound (F-V) of the presentinvention from a compound (F-I) (equivalent to the compound (C-II) thatis used in Method C).

wherein R¹, R², R³, and Tf are the same as defined above.

(Step F1) Step of Cyanization Using a Transition Metal Catalyst

This is a step of obtaining a compound (F-II) from a compound (F-I) inthe presence of zinc cyanide and a palladium catalyst and in thepresence or absence of a phosphine.

Examples of the palladium catalyst include tris(dibenzylideneacetone)dipalladium, bis[tri(tert-butyl)phosphine]palladium, tetrakis(triphenylphosphine)palladium and bis(trifluoroacetoxy)palladium.

Examples of the phosphine include triphenylphosphine,tri(tert-butyl)phosphine, tri-o-toluylphosphine,diphenylphosphinoferrocene and diphenylphosphinobutane. As a solvent,N-methyl-2-pyrrolidone or N,N-dimethyl formamide or a mixture of thesecan be mentioned.

The reaction temperature is usually about 80 to 120° C. and reactiontime is usually about 1 to 8 hours.

(Step F2) Step of Adding Hydroxylamine

This is a step of obtaining a compound (F-III) from a compound (F-II) byuse of a hydroxylamine.

As a solvent, methanol, ethanol, dimethylsulfoxide, water or a mixtureof these solvents can be mentioned.

The reaction temperature is usually about room temperature to 100° C.and the reaction time is usually about 0.5 to 24 hours.

(Step F3) Step of Acylating Oxime

This is a step of obtaining a compound (F-IV) from a compound (F-III) byuse of the corresponding carboxylic acid in the presence of a condensingagent and a base.

Examples of the condensing agent include0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethylrhoniumhexafluorophosphate (HATU),4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine (DMT-MM) and1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC or EDCI).

Examples of the base include triethylamine, diisopropylethylamine anddimethylaminopyridine.

An additive such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole(HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) is sometimesadvantageously used in order to make the reaction progress smoothly.

As a solvent, ethanol, tetrahydrofuran, acetonitrile,N,N-dimethylformamide, dichloromethane, toluene or a mixture of thesesolvents can be mentioned.

The reaction temperature is usually about room temperature to 60° C. andthe reaction time is usually about 0.5 to 24 hours.

(Step F4) Cyclization Step

This is a step of obtaining a compound (F-V) by stirring a compound(F-IV) in a solvent at room temperature or under heating.

As the solvent, toluene, N,N-dimethylformamide, dichloromethane,tetrahydrofuran, acetonitrile or a mixture of these can be mentioned.

The reaction temperature is usually about 60 to 120° C. and the reactiontime is usually about 0.5 to 24 hours.

[Method G]

Method G is a method of producing a compound (G-III) of the presentinvention from a compound (G-I).

wherein R¹, R², R³, A and X are the same as defined above.

(Step G1) Demethylation Step

This is a step of obtaining a compound (G-II) from a compound (G-I) inthe same manner as in (Step B1).

(Step G2) Alkylation Step

This is a step of obtaining a compound (G-III) from a compound (G-II) inthe same manner as in (Step A2).

[Method H]

Method H is a method of producing a compound (H-I) of the presentinvention from a compound (H-II) by removing a protecting groupcontained in R^(1′) or R^(3′) to convert it into R¹ or R³.

wherein R¹, R², R³ and A are the same as defined above; R^(1′) andR^(3′) represent protected R¹ and R³, for example, a hydroxyC1-C6 alkylgroup protected with a protecting group such as a tetrahydropyranylgroup and a t-butyldimethylsilyl group, if R¹ is a hydroxyC1-C6 alkylgroup.

(H1 Step) Deprotection Step

(Case of Tetrahydropyranyl (THP) Group)

This is a step of obtaining a compound (H-II) from a compound (H-I)containing a hydroxy group protected with a tetrahydropyranyl group byuse of an acid.

Examples of the acid include hydrochloric acid, sulfuric acid,hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane, hydrochloricacid-ethyl acetate, acetic acid, p-toluenesulfonic acid and pyridiniump-toluenesulfonate.

As a solvent, methanol, ethanol, tetrahydrofuran, water or a mixture ofthese can be mentioned.

The reaction temperature is usually about 0 to 80° C. and the reactiontime is usually about 0.5 to 24 hours.

(Case of Silyl Group)

In this step, the silyl group refers to a silyl group that is generallyused as a protecting group in synthesis, such as a trimethylsilyl groupand a t-butyldimethylsilyl group.

This is a step of obtaining a compound (H-II) from a compound (H-I)containing a hydroxy group and protected with a silyl group by use of adesilylation reagent.

Examples of the desilylation reagent include an acid andtetrabutylammonium fluoride (TBAF), hydrogen fluoride and hydrogenfluoride pyridine.

Examples of the acid include hydrochloric acid, sulfuric acid,hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane, hydrochloricacid-ethyl acetate, acetic acid, p-toluenesulfonic acid and trifluoroacetic acid. The acid can be used in a reaction in a catalytic amount.

As a solvent, methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane,1,4-dioxane, acetonitrile, water or a mixture of these can be mentioned.

The reaction temperature is usually about 0 to 60° C. and the reactiontime is usually about 0.5 to 24 hours.

The compounds produced by the above methods can be isolated and purifiedby a method known in the art, such as extraction, precipitation,distillation, chromatography, fractional recrystallization andrecrystallization.

If a compound or an intermediate has an asymmetric carbon, it hasoptical isomers. These optical isomers can be mutually isolated andpurified by a conventional method such as fractional recrystallization(salt fractionation) using recrystallization with a proper salt, andcolumn chromatography. For a method of fractionating an optical isomerfrom a racemic body, refer to the document: J. Jacques et al,“Enantiomers, Racemates and Resolution, John Wiley And Sons, Inc.”.

(Dosage Form)

As an administration route, oral administration using a tablet, a pill,a capsule, a granule, a powder or a liquid; or parenteral administrationusing an injection such as intra-articular, intravenous or intramuscularinjections, a suppository, an eye drop, an eye ointment, a transdermalliquid, an ointment, a transdermal patch, a transmucosal liquid, atransmucosal patch or an inhalant, may be employed.

As a solid composition for oral administration, e.g., tablets, powdersand granules are used. In such a solid composition, one or two or moreactive ingredients are mixed with at least one type of inactiveexcipient such as lactose, mannitol, dextrose, hydroxypropyl cellulose,microcrystalline cellulose, starch, polyvinylpyrrolidone and/ormagnesium aluminometasilicate. In such a composition, an inactiveadditive such as a lubricant (e.g., magnesium stearate), a disintegrantsuch as sodium carboxymethyl starch, a stabilizer and/or a solubilizer,may be added in accordance with a conventional method. Tablets or pills,if necessary, may be coated with sugar, a film soluble in the stomach oran enteric film.

Examples of a liquid composition for oral administration include apharmacologically acceptable emulsion, solution, suspension, syrup andelixir. Such a liquid composition contains an inactive diluent that isgenerally used, such as purified water or ethanol. The liquidcomposition may contain an additive such as a solubilizer, a wettingagent or a suspending agent, a sweetener, a flavor, an aroma material oran antiseptic agent, other than the inactive diluent.

Examples of an injection for parenteral administration include anaqueous or non-aqueous aseptic solution, suspension and emulsion.Examples of the aqueous solvent include distilled water for injectionand physiological saline. Examples of the nonaqueous solvent includepropylene glycol, polyethylene glycol, a vegetable oil such as oliveoil, an alcohol such as ethanol and Polysorbate 80. Such a compositionmay further contain a tonicity agent, a preservative, a wetting agent,an emulsifying agent, a dispersant, a stabilizer or a solubilizingagent. Such a composition is sterilized, for example, by filtrationthrough a sterilization filter, addition of a disinfectant orirradiation. Alternatively, an aseptic solid composition is produced anddissolved or suspended in aseptic water or aseptic solvent for injectionjust before use and then put in use.

Examples of an external formulation include an ointment, a plaster, acream, a jelly, a cataplasm, a spray, a lotion, an eye drop and an eyeointment. Such an external formulation contains, e.g., an ointment base,a lotion base, an aqueous or non-aqueous solution, a suspension or anemulsion that is generally used. Examples of the ointment or lotion baseinclude polyethylene glycol, propylene glycol, white petrolatum,beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate,stearyl alcohol, cetyl alcohol, lauromacrogol and sorbitan sesquioleate.

As an inhalation and a transmucosal agent such as a transnasal agent, asolid, liquid or semi-solid composition is used and can be produced by amethod known in the art. Such an agent may appropriately contain, forexample, an excipient known in the art, further, a pH adjuster, apreservative, a surfactant, a lubricant, a stabilizer or a thickener. Anappropriate device for inhalation or insufflation can be used foradministration; more specifically, a device known in the art such as ametered dose inhalation device or a spray is used. A compound (of theinvention) may be administered alone or as a composition, in the form ofpowder; or used in combination with a pharmaceutically acceptablecarrier in the form of a solution or suspension. An inhaler such as adry powder inhaler may be used for single administration or multipleadministrations. A dry powder or a powder-containing capsule can beused. Alternatively, the inhaler may be a pressurized aerosol sprayusing an appropriate propellant, i.e., a suitable gas such aschlorofluoroalkane, hydrofluoroalkane or carbon dioxide.

(Dosage Amount)

In the case of oral administration, the proper dosage amount per day perweight is generally about 0.001-100 mg/kg, preferably 0.1-30 mg/kg, andmore preferably 0.1-10 mg/kg. This is administered in a single dose orin two or more doses. In the case of intravenous administration, theproper dosage amount per day per weight is about 0.0001-10 mg/kg andadministered in a single dose per day or in a plurality of doses. In thecase of a transmucosal agent, the dosage amount per weight is about0.001-100 mg/kg, which is administered in a single dose or in aplurality of doses. The dosage amount is appropriately and individuallydetermined in consideration of the symptoms, age and sex of theindividual.

(Combined Use)

In the present invention, the compound of the invention can be used incombination with various types of therapeutic agents or prophylacticagents expected to have an effect on a disease. The agent to be used incombination may be administered simultaneously or sequentially orintermittently at desired time intervals. The formulations to besimultaneously administered may be a combination drug or separate drugs.

(Formulation Example 1) Powdered Medicine

The compound of the present invention (5 g), lactose (895 g) and cornstarch (100 g) were mixed in a blender to obtain powdered medicine.

(Formulation Example 2) Granule

The compound of the present invention (5 g), lactose (865 g) and lowsubstituted hydroxypropyl cellulose (100 g) were mixed and then a 10%aqueous solution of hydroxypropyl cellulose (300 g) was added theretoand the mixture was kneaded, granulated by an extrusion granulator, anddried to obtain granules.

(Formulation Example 3) Tablet

The compound of the present invention (5 g), lactose (90 g), corn starch(34 g), crystalline cellulose (20 g) and magnesium stearate (1 g) weremixed in a blender and compressed into tablets by a tablet machine toobtain tablets.

Pharmacological activity of the compound of the present invention or apharmacologically acceptable salt thereof was checked by the followingtest.

(Test Example) Determination of TNF-α Inhibition Rate

A test substance was suspended in a 0.5% (w/v) methyl cellulose andorally administered to mice at a dose of 100 mg/kg. One hour later, alipopolysaccharide (LPS, Sigma-Aldrich, L2630 (trade name)) (0.4 mg/kg)was intraperitoneally administered to induce inflammation. One hourafter administration of LPS, blood was taken from the vena cava underanesthesia with isoflurane, placed in a tube containing a serumseparating agent, allowed to stand still at room temperature for 20-30minutes and centrifuged at 4° C. at 12,000 rpm for 5 minutes to obtainthe serum. Thereafter, the amount of the TNF-α in the serum was measuredby using Mouse TNF-α Elisa Kit (Invitrogen, KMC3011C (trade name)) orMouse TNF-α Immunoassay Kit (PerkinElmer, AL505 (trade name)) inaccordance with the protocol of the kit. The serum was diluted 10 timeswith the dilution solution contained in the kit and put in use.

TNF-α inhibition rate (%) of the test substance was calculated inaccordance with the following expression.

TNF-α inhibition rate (%)=[(TNF-α amount of control group)−(TNF-α amountof test substance administration group)]×100/(TNF-α amount of controlgroup)

TABLE 1 TNF-α inhibition Example No. rate (%) Griseofulvin 19  1 62  271  3 65  4 73  5 70  6 55  7 65  8 38  9 65 10 58 11 61 12 61 13 82 1424 15 55 16 62

EXAMPLES

Now, the present invention will be more specifically described by way ofExamples and the Test Example. However, the present invention is notlimited by these.

In the following Examples, nuclear magnetic resonance (hereinafterreferred to as 1H NMR) spectra were obtained by using tetramethylsilaneas a standard substance and chemical shift values were expressed by 6values (ppm). In a splitting pattern, a singlet was represented by s, adoublet d, a triplet t, a quartet q, a multiplet m and a broad br.

Example 1(2S,5′R)-7-Chloro-6-(2-hydroxyethoxy)-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione1a(2S,5′R)-7-Chloro-6-hydroxy-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

(+)-Griseofulvin (CAS number: 126-07-8, product code: G0384(manufactured by Tokyo Kasei Kogyo Co., Ltd.)) (50 g), potassium iodide(23.5 g) and 18-crown-6-ether (41.2 g) were dissolved in pyridine (500mL), stirred at 120° C. for 9 hours and allowed to stand still at roomtemperature overnight.

The reaction mixture was concentrated. To this, aqueous 4% sodiumbicarbonate was added. The reaction mixture was washed twice with ethylacetate. The aqueous layer was neutralized with 1 mol/l hydrochloricacid and extracted with ethyl acetate. The organic layer was washed withwater and saturated saline and dried over anhydrous sodium sulfate. Thesolvent was distilled away under reduced pressure and the resultantresidue was purified by silica gel column chromatography [elutionsolvent: dichloromethane/ethanol=99/1 (V/V)] to obtain a crude product(19.4 g)

Ethyl acetate was added to the crude product to solidify it. The mixturewas subjected to filtration to obtain the title compound (15.2 g (yield:32%)) as a white solid.

1b(2S,5′R)-7-Chloro-6-(2-hydroxyethoxy)-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 1 (1a):(2S,5′R)-7-chloro-6-hydroxy-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.1 g) was dissolved in N,N-dimethylformamide (3 mL). To this,2-bromoethanol (0.0738 g) and potassium carbonate (0.102 g) were addedand stirred at 100° C. for 6 hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: ethyl acetate] to obtain thetitle compound (38 mg (yield: 34%)) as a light yellow solid.

Example 2(2S,5′R)-7-Chloro-3′,4-dimethoxy-6-(2-methoxyethoxy)-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 1 (1a):(2S,5′R)-7-chloro-6-hydroxy-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(30 mg) was dissolved in N,N-dimethylformamide (1 mL). To this,2-bromoethyl methyl ether (136 mg) and potassium carbonate (135 mg) wereadded. The reaction mixture was stirred at 80° C. for 6 hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: ethyl acetate] to obtain thetitle compound (20 mg (yield: 57%)) as a white solid.

Example 3(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(1-methylpyrazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione3a[(2S,5′R)-7-Chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate

The compound of Example 1 (1a):(2S,5′R)-7-chloro-6-hydroxy-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(20 g) was dissolved in dichloromethane (300 mL). To this,N-phenylbis(trifluoromethanesulfonimide) (25.3 g) and triethylamine(20.6 mL) were added. The reaction solution was allowed to stand stillat room temperature overnight.

The reaction solution was diluted with dichloromethane. The organiclayer was washed with water and saturated saline and dried overanhydrous sodium sulfate. The solvent was distilled away under reducedpressure and the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=8/2-3/7 (V/V)]to obtain the title compound (23.5 g (yield: 85%)) as a white solid.

3b(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(1-methylpyrazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 3 (3a):[(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate (76 mg) was dissolved in N,N-dimethylformamide(1.6 mL). To this,1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.0403 g), potassium carbonate (0.0669 g) and[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloridedichloromethane additive (0.0131 g) were added at room temperature. Themixture was stirred at 80° C. for 3 hours.

After the temperature of the reaction mixture had returned to roomtemperature, the reaction mixture was diluted with ethyl acetate andinsoluble matter was filtered off. The filtrate was poured into waterand extracted with ethyl acetate. The organic layer was washed withwater and saturated saline and dried over anhydrous sodium sulfate. Thesolvent was distilled away under reduced pressure and the resultantresidue was purified by silica gel column chromatography [elutionsolvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)] to obtain the titlecompound (27 mg (yield: 42%)) as a white solid.

Example 4(2S,5′R)-7-Chloro-6-(1-ethylpyrazol-3-yl)-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 3 (3a):[(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate (0.5 g) was dissolved in toluene (10 mL). Tothis,1-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.283 g),chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium (II) (0.167 g) and saturatedaqueous solution of sodium hydrogen carbonate (5 mL) were added. Thereaction mixture was stirred at 90° C. for two hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: n-hexane/ethylacetate=1/1-0/1 (V/V)] to obtain the title compound (266 mg (yield:60%)) as a white solid.

Example 5(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione5a (2,4,6-Trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate

The compound of Example 3 (3a):[(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate (20 g) was dissolved in toluene (200 mL). Tothis, palladium acetate (II) (0.477 g),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.46 g) andN,N-diisopropylethylamine (14.8 mL) were added. The reaction mixture washeated to 80° C.

2,4,6-Trichlorophenyl formate (12.5 g) was divided into three portions,which were added at intervals of 30 minutes to the reaction mixture.

After the reaction mixture was stirred at 80° C. for 30 minutes, thereaction mixture was poured into water and extracted with ethyl acetate.The organic layer was washed with water and saturated saline and driedover anhydrous sodium sulfate. The solvent was distilled away underreduced pressure and the resultant residue was purified by silica gelcolumn chromatography [elution solvent: n-hexane/ethyl acetate=7/3-3/7(V/V)] to obtain the title compound (19.5 g (yield: 84%)) as a whitesolid.

5b(2S,5′R)—N′-Acetyl-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide

The compound of Example 5 (5a): 2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(35 g) was dissolved in dichloromethane (400 mL). To this,3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (8.72 g), acetohydrazide (purity:90%, 7.12 g), 4-dimethylaminopyridine (0.783 g) and triethylamine (26.8mL) were added. The reaction solution was allowed to stand still at roomtemperature overnight.

The reaction solution was washed with water and saturated saline anddried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/9 (V/V)] to obtain the title compound (23.4 g (yield:86%)) as a white solid.

5c(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 5 (5b):(2S,5′R)—N′-acetyl-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide(0.25 g) was dissolved in toluene (5 mL) and anhydrous 1,4-dioxane (5mL). To this, a (methoxycarbonylsulfamoyl)triethylammonium hydroxideinner salt (0.169 g) was added. The reaction mixture was stirred at 60°C. for one hour.

To the reaction mixture, water was added. The reaction mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated saline and dried over anhydrous sodium sulfate. The solventwas distilled away under reduced pressure and the resultant residue waspurified by silica gel column chromatography [elution solvent:n-hexane/ethyl acetate=1/1-0/1 (V/V)] to obtain the title compound (49mg (yield: 20%)) as a white solid.

Example 6(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione6a [(Z)-1-Aminoethylideneamino](2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate

The compound of Example 5 (5a): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(3 g) was dissolved in dichloromethane (50 mL). To this,N′-hydroxyethanimidamide (0.488 g), 3H-1,2,3-triazolo[4,5-b]pyridin-3-ol(0.748 g), 4-dimethylaminopyridine (0.0671 g) and triethylamine (2.28mL) were added. The reaction solution was allowed to stand still at roomtemperature overnight.

The reaction solution was diluted with ethyl acetate and the organiclayer was washed with water and saturated saline and dried overanhydrous sodium sulfate. The solvent was distilled away under reducedpressure and the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=80/20-0/100(V/V)] to obtain the title compound (2.32 g (yield: quantitative)) as awhite solid.

6b(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 6 (6a): [(Z)-1-aminoethylideneamino](2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.95 g) was dissolved in toluene (20 mL). The reaction solution wasstirred at 110° C. for 6 hours and concentrated. The resultant residuewas purified by silica gel column chromatography [elution solvent:n-hexane/ethyl acetate=8/2-3/7 (V/V)] and triturated with n-hexane andethyl acetate to obtain the title compound (756 mg (yield: 83%)) as awhite solid.

Example 7(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione7a(2S,5′R)-7-Chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbonitrile

The compound of Example 3 (3a):[(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate (1 g) was dissolved in N,N-dimethylformamide(10 mL). To this, tetrakis(triphenylphosphine)palladium (0) (0.245 g)and zinc cyanide (0.499 g) were added. The reaction mixture was stirredat 90° C. for 5 hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: n-hexane/ethylacetate=8/2-3/7 (V/V)] to obtain the title compound (540 mg (yield: 73%)as a light yellow solid.

7b(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 7 (7a):(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbonitrile(0.54 g) was dissolved in ethanol (10 mL). To this, 50% hydroxylaminesolution (0.19 mL) was added. The reaction solution was stirred at 90°C. for 6 hours.

The reaction solution was concentrated and subjected to azeotropicdistillation twice with toluene. The residue was dissolved indichloromethane (20 mL). To this, acetic acid (0.0891 mL),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.299 g),3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.0424 g) and triethylamine (0.652mL) were added. The reaction solution was stirred at room temperaturefor 5 hours.

The reaction solution was diluted with dichloromethane and the organiclayer was washed with water and saturated saline and dried overanhydrous sodium sulfate. The solvent was distilled away under reducedpressure and the resultant residue was roughly purified by silica gelcolumn chromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1(V/V)]. The resultant crude product was suspended in toluene (5 mL) andthe suspension solution was stirred at 100° C. for 7 hours.

To the reaction mixture, water was added, and the reaction mixture wasextracted with ethyl acetate. The organic layer was washed with waterand saturated saline and dried over anhydrous sodium sulfate. Thesolvent was distilled away under reduced pressure and the resultantresidue was purified by silica gel column chromatography [elutionsolvent: n-hexane/ethyl acetate=7/3-2/8 (V/V)] to obtain the titlecompound (34 mg (yield: 5.4%, 3 steps)) as a white solid.

Example 8(2S,5′R)-7-Chloro-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione8a(2S,5′R)-7-Chloro-N′-(2-hydroxy-2-methyl-propanoyl)-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide

The compound of Example 5 (5a): 2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.5 g) was dissolved in dichloromethane (10 mL). To this,2-hydroxy-2-methylpropanohydrazide (0.162 g),3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.125 g), 4-dimethylaminopyridine(0.0224 g) and triethylamine (0.639 mL) were added. The reaction mixturewas allowed to stand still at room temperature overnight.

The solvent was distilled away under reduced pressure and the resultantresidue was purified by silica gel column chromatography [elutionsolvent: methanol/ethyl acetate=0/10-1/9 (V/V)] to obtain the titlecompound (415 mg (yield: 97%)) as a white solid.

8b(2S,5′R)-7-Chloro-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 8 (8a):(2S,5′R)-7-chloro-N′-(2-hydroxy-2-methyl-propanoyl)-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide(0.415 g) was dissolved in dichloromethane (5 mL). To this,triethylamine (0.62 mL) and p-toluenesulfonyl chloride (0.254 g) wereadded. The reaction mixture was stirred at room temperature for twohours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/9 (V/V)] to obtain the title compound (141 mg (yield:35%)) as a white solid.

Example 9(2S,5′R)-7-Chloro-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione9a (2S)-2-Tetrahydropyran-2-yloxypropanehydrazide

Methyl (2S)-2-tetrahydropyran-2-yloxypropanoate (CAS Registry Number:153829-63-1, J. Org. Chem. 1991, 56, 1088-1093) (2.2 g) was dissolved inethanol (8 mL). To this, hydrazine monohydrate (1.8 g) was added. Thereaction mixture was allowed to stand still at room temperatureovernight. The solvent was distilled away under reduced pressure and theresultant residue was purified by silica gel column chromatography[elution solvent: methanol/ethyl acetate=0/10-1/9 (V/V)] to obtain thetitle compound (1.6 g (yield: 73%)) as a white solid.

9b(2S,5′R)-7-Chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-N′-[(2S)-2-tetrahydropyran-2-yloxypropanoyl]spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide

The compound of Example 5 (5a): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.5 g) was dissolved in dichloromethane (10 mL). To this, the compoundof Example 9 (9a): (2S)-2-tetrahydropyran-2-yloxypropanehydrazide (0.258g), 3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.125 g),4-dimethylaminopyridine (0.0112 g) and N,N-diisopropylethylamine (0.478mL) were added. The reaction mixture was allowed to stand still at roomtemperature overnight.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (490 mg (yield: quantitative)) as a whitesolid.

9c(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-[5-[(1S)-1-tetrahydropyran-2-yloxyethyl]-1,3,4-oxadiazol-2-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 9 (9b):(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-N′-[(2S)-2-tetrahydropyran-2-yloxypropanoyl]spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide(0.49 g) was dissolved in dichloromethane (5 mL). To this, triethylamine(0.637 mL) and p-toluenesulfonyl chloride (0.209 g) were added. Thereaction mixture was stirred at room temperature for three hours.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (452 mg (yield: 95%)) as a white solid.

9d(2S,5′R)-7-Chloro-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 9 (9c):(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-[5-[(1S)-1-tetrahydropyran-2-yloxyethyl]-1,3,4-oxadiazol-2-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.452 g) was dissolved in ethanol (4 mL). To this, water (1 mL) andp-toluenesulfonic acid monohydrate (0.0828 g) were added. The reactionmixture was stirred at 50° C. for one hour.

The reaction mixture was poured into water and 1 mol/l hydrochloric acidwas added thereto. The reaction mixture was extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/1-1/19 (V/V)] to obtain the title compound (119 mg (yield:31%)) as a white solid.

Example 10(2S,5′R)-7-Chloro-6-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione10a (2R)-2-Tetrahydropyran-2-yloxypropanehydrazide

Methyl (2R)-2-tetrahydropyran-2-yloxypropanoate (CAS Registry Number:124508-74-3, Tetrahedron, 2012, 68, 2068-2073) (1.6 g) was dissolved inethanol (8 mL). To this, hydrazine monohydrate (1.2 mL) was added. Thereaction mixture was stirred at 90° C. for 4 hours.

After the reaction mixture was allowed to stand still at roomtemperature overnight, the mixture was stirred at 90° C. for 10 hours.The mixture was further allowed to stand at room temperature overnightand then stirred at 90° C. for 10 hours. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/1-1/9 (V/V)] to obtain the title compound (1 g (yield: 62%))as a white solid.

10b(2S,5′R)-7-Chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-N′-[(2R)-2-tetrahydropyran-2-yloxypropanoyl]spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide

The compound of Example 5 (5a): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.5 g) was dissolved in dichloromethane (10 mL). To this, the compoundof Example 10 (10a): (2R)-2-tetrahydropyran-2-yloxypropanehydrazide(0.19 g), 3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.124 g),4-dimethylaminopyridine (0.0112 g) and N,N-diisopropylethylamine (0.478mL) were added. The reaction mixture was allowed to stand still at roomtemperature overnight.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: methanol/ethyl acetate=0/10-1/9 (V/V)]to obtain the title compound (460 mg (yield: 94%)) as a white solid.

10c(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-[5-[(1R)-1-tetrahydropyran-2-yloxyethyl]-1,3,4-oxadiazol-2-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 10 (10b):(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-N′-[(2R)-2-tetrahydropyran-2-yloxypropanoyl]spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide(0.46 g) was dissolved in dichloromethane (5 mL). To this, triethylamine(0.598 mL) and p-toluenesulfonyl chloride (0.196 g) were added. Thereaction mixture was stirred at room temperature for two hours.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (315 mg (yield: 71%)) as a white solid.

10d(2S,5′R)-7-Chloro-6-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 10 (10c):(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-[5-[(1R)-1-tetrahydropyran-2-yloxyethyl]-1,3,4-oxadiazol-2-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.315 g) was dissolved in ethanol (4 mL). To this, water (1 mL) andp-toluenesulfonic acid monohydrate (0.0577 g) were added. The reactionmixture was stirred at 50° C. for one hour.

The reaction mixture was poured into water and 1 mol/l hydrochloric acidwas added thereto. The reaction mixture was extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/19 (V/V)] to obtain the title compound (112 mg (yield:42%)) as a white solid.

Example 11(2S,5′R)-7-Chloro-4-ethoxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione11a(2S,5′R)-7-Chloro-4-hydroxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

Magnesium chips (0.41 g) were added in diethyl ether (60 mL) and iodine(3.9 g) was divided into three portions, which were added at intervalsof 20 minutes. The reaction mixture was stirred at room temperature forone hour, and then, the compound of Example 8 (8b):(2S,5′R)-7-chloro-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(6.3 g) and toluene (150 mL) were added thereto. The reaction mixturewas stirred at 90° C. for 7 hours.

To the reaction mixture, water was added. The mixture was neutralizedwith 1 mol/l hydrochloric acid, and then, made slightly alkaline byadding saturated aqueous sodium bicarbonate. The reaction mixture wasextracted with ethyl acetate. The organic layer was washed with 1 mol/lhydrochloric acid and saturated saline and dried over anhydrous sodiumsulfate. The solvent was distilled away under reduced pressure and theresultant residue was purified by silica gel column chromatography[elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)] to obtain thetitle compound (2.7 g (yield: 44%)) as a white solid.

11b(2S,5′R)-7-Chloro-4-ethoxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 11 (11a):(2S,5′R)-7-chloro-4-hydroxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.3 g) was dissolved in N,N-dimethylformamide (4 mL). To this,potassium carbonate (0.191 g) and iodoethane (0.0827 mL) were added. Thereaction mixture was stirred at 80° C. for two hours.

The reaction mixture was poured into water, neutralized with 1 mol/1hydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=6/4-1/9 (V/V)]to obtain the title compound (42 mg (yield: 13%)) as a white solid.

Example 12(2S,5′R)-7-Chloro-4-ethoxy-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3′-methoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

Magnesium chips (0.073 g) were added in diethyl ether (20 mL) and asmall amount of iodine (0.70 g) was added thereto. The reaction mixturewas stirred at room temperature for 10 minutes. Further, iodine (0.70 g)was divided into three portions, which were added at intervals of 20minutes. After the reaction mixture was stirred at room temperature for30 minutes, toluene (50 mL), the compound of Example 9 (9c):(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-[5-[(1S)-1-tetrahydropyran-2-yloxyethyl]-1,3,4-oxadiazol-2-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(1.3 g) were added thereto. The reaction mixture was stirred at 80° C.for 8 hours.

To the reaction mixture, water was added. The mixture was neutralizedwith 1 mol/l hydrochloric acid and extracted with ethyl acetate. Theorganic layer was washed with saturated saline and dried over anhydroussodium sulfate.

The solvent was distilled off under reduced pressure and the resultantresidue was dissolved in N,N-dimethylformamide (10 mL). To this,potassium carbonate (1.36 g) and iodoethane (0.485 mL) were added. Thereaction mixture was stirred at 80° C. for one hour. The reactionmixture was poured into water, neutralized with 1 mol/l hydrochloricacid and extracted with ethyl acetate. The organic layer was washed withwater and saturated saline and dried over anhydrous sodium sulfate. Thesolvent was distilled away under reduced pressure and the resultantresidue was purified by silica gel column chromatography [elutionsolvent: n-hexane/ethyl acetate=7/3-2/8 (V/V)]. The solid obtained wastriturated with n-hexane and ethyl acetate to obtain the title compound(122 mg (yield: 13%)) as a white solid.

Example 13(2S,5′R)-7-Chloro-6-[3-(1-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione13a 2-Tetrahydropyran-2-yloxypropanenitrile

2-Hydroxypropanenitrile (5.0 g) was dissolved in dichloromethane (150mL). To this, 3,4-dihydro-2H-pyran (7.7 g) and p-toluenesulfonic acidmonohydrate (1.3 g) were added. The reaction solution was stirred atroom temperature for 14 hours. To the reaction solution, triethylaminewas added, and then, the solvent was distilled off under reducedpressure. The resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=97/3-7/3 (V/V)]to obtain the title compound, more specifically, two types ofdiastereomer (5.7 g (yield: 52%) and 2.5 g (yield: 23%), respectively)as light yellow solids.

13b N′-Hydroxy-2-tetrahydropyran-2-yloxy-propanamidine

One of the diastereomers obtained in Example 13 (13a):2-tetrahydropyran-2-yloxypropanenitrile (5.6 g) was dissolved in ethanol(36 mL). To this, a 50% hydroxylamine solution (4.3 mL) was added. Thereaction mixture was heated to 80° C. and stirred for 5 hours. After thetemperature of the reaction mixture had returned to room temperature,the solvent was distilled off under reduced pressure. The resultantresidue was purified by silica gel column chromatography [elutionsolvent: n-hexane/ethyl acetate=10/1-1/0 (V/V)] to obtain the titlecompound (5.0 g (yield: 74%) as a light yellow solid.

13c [(Z)-(1-Amino-2-tetrahydropyran-2-yloxy-propylidene)amino](2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate

The compound of Example 5 (5a): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.5 g) was dissolved in dichloromethane (10 mL). To this, the compoundof Example 13 (13b): N′-hydroxy-2-tetrahydropyran-2-yloxy-propanamidine(0.207 g), 3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.125 g),4-dimethylaminopyridine (0.0112 g) and N,N-diisopropylethylamine (0.478mL) were added. The reaction mixture was stirred at room temperature for5 hours.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (410 mg (yield: 83%)) as a white solid.

13d(2S,5′R)-7-Chloro-3′,4-dimethoxy-5′-methyl-6-[3-(1-tetrahydropyran-2-yloxyethyl)-1,2,4-oxadiazol-5-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 13 (13c):[(Z)-(1-amino-2-tetrahydropyran-2-yloxy-propylidene)amino](2S,5′R)-7-chloro-1′,4-dimethoxy-5′-methyl-3,3′-dioxo-spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.41 g) was dissolved in toluene (5 mL). The reaction mixture wasstirred at 110° C. for 7 hours. The solvent was distilled away underreduced pressure and the resultant residue was purified by silica gelcolumn chromatography [elution solvent: n-hexane/ethyl acetate=1/1-1/9(V/V)] to obtain the title compound (375 mg (yield: 95%)) as a whitesolid.

13e(2S,5′R)-7-Chloro-6-[3-(1-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3′,4-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 13 (13d):(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-[3-(1-tetrahydropyran-2-yloxyethyl)-1,2,4-oxadiazol-5-yl]spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.375 g) was dissolved in ethanol (4 mL). To this, p-toluenesulfonicacid monohydrate (0.0687 g) and water (1 mL) were added. The reactionmixture was stirred at room temperature for 8 hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: n-hexane/ethylacetate=1/1-0/1 (V/V)] to obtain the title compound (195 mg (yield:62%)) as a white solid.

Example 14(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione14a(2S,5′R)-7-Chloro-4-hydroxy-3′,6-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

Magnesium chips (1.03 g) were added in diethyl ether (50 mL) and iodine(8.63 g) was added thereto little by little over one hour. After thereaction mixture was stirred at room temperature for 30 minutes, toluene(100 mL) and (+)-griseofulvin (10 g) were added thereto. The reactionmixture was stirred at 80° C. for three hours.

To the reaction mixture, water was added. The mixture was neutralizedwith 1 mol/l hydrochloric acid and extracted with ethyl acetate. Theorganic layer was washed with a saturated saline and dried overanhydrous sodium sulfate. The solvent was distilled away under reducedpressure and the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (7.8 g (yield: 81%)) as a white solid.

14b(2S,5′R)-7-Chloro-3′,6-dimethoxy-5′-methyl-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 14 (14a):(2S,5′R)-7-chloro-4-hydroxy-3′,6-dimethoxy-5′-methyl-spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(5.1 g) was dissolved in N,N-dimethylformamide (60 mL). To this,2-(2-bromoethoxy)tetrahydro-2H-pyran (3.8 g) and potassium carbonate(6.2 g) were added. The reaction mixture was stirred at 80° C. for 7hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: n-hexane/ethylacetate=8/2-3/7 (V/V)] to obtain the title compound (6.9 g (yield: 98%))as a white solid.

14c(2S,5′R)-7-Chloro-6-hydroxy-3′-methoxy-5′-methyl-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 14 (14b):(2S,5′R)-7-chloro-3′,6-dimethoxy-5′-methyl-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(6.9 g) was dissolved in pyridine (70 mL). To this, 18-crown-6-ether(4.3 g) and potassium iodide (2.5 g) were added. The reaction mixturewas stirred at 120° C. for 8 hours.

The reaction solution was concentrated and the reaction mixture waspoured into water and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1 (V/V)]to obtain the title compound (3.8 g (yield: 57%)) as a white solid.

14d[(2S,5′R)-7-Chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate

The compound of Example 14 (14c):(2S,5′R)-7-chloro-6-hydroxy-3′-methoxy-5′-methyl-4-(2-tetrahydropyran-2-yloxyethoxy)spirobenzofuran-2,4′-cyclohexa-2-ene]-1′,3-dione (3.8 g) was dissolvedin dichloromethane (40 mL). To this, triethylamine (2.9 mL) andN-phenylbis(trifluoromethanesulfonimide) (3.6 g) were added. Thereaction mixture was allowed to stand still at room temperatureovernight.

The reaction solution was diluted with dichloromethane. The organiclayer was washed with water and saturated saline and dried overanhydrous sodium sulfate. The solvent was distilled away under reducedpressure and the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=8/2-4/6 (V/V)]to obtain the title compound (3.2 g (yield: 65%)) as a white solid.

14e (2,4,6-Trichlorophenyl)(2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate

The compound of Example 14 (14d):[(2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-yl]trifluoromethanesulfonate (1 g) was dissolved in toluene (200 mL). Tothis, palladium acetate (II) (0.0192 g),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.0989 g) andN,N-diisopropylethylamine (0.596 mL) were added. The reaction mixturewas heated to 80° C.

2,4,6-Trichlorophenyl formate (0.501 g) was divided into three portions,which were added at intervals of 10 minutes. The reaction mixture wasstirred at 80° C. for 30 minutes, and then, the temperature of themixture was returned to room temperature. The reaction mixture waspoured into water and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: n-hexane/ethyl acetate=8/2-4/6 (V/V)]to obtain the title compound (850 mg (yield: 75%)) as a white solid.

14f(2S,5′R)—N′-Acetyl-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide

The compound of Example 14 (14e): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.4 g) was dissolved in dichloromethane (20 mL). To this,acetohydrazide (purity: 90%, 0.0673 g),3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.0824 g), 4-dimethylaminopyridine(0.0148 g) and triethylamine (0.254 mL) were added. The reaction mixturewas allowed to stand still at room temperature overnight.

The reaction mixture was poured into water, neutralized with 1 mol/lhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: methanol/ethyl acetate=0/10-1/9 (V/V)]to obtain the title compound (280 mg (yield: 86%)) as a white solid.

14g(2S,5′R)-7-Chloro-3′-methoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 14 (14f):(2S,5′R)—N′-acetyl-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carbohydrazide(0.28 g) was dissolved in dichloromethane (5 mL). To this,p-toluenesulfonyl chloride (0.149 g) and triethylamine (0.364 mL) wereadded. The reaction mixture was stirred at room temperature for threehours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: n-hexane/ethylacetate=1/1-0/1 (V/V)] to obtain the title compound (202 mg (yield:75%)) as a white solid.

14h(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 14 (14 g):(2S,5′R)-7-chloro-3′-methoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.202 g) was dissolved in ethanol (2 mL). To this, p-toluenesulfonicacid monohydrate (0.037 g) and water (5 mL) were added. The reactionmixture was stirred at 50° C. for two hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/9 (V/V)] to obtain the title compound (39 mg (yield:23%)) as a white solid.

Example 15(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione15a [(Z)-1-Aminoethylideneamino](2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate

The compound of Example 14 (14e): (2,4,6-trichlorophenyl)(2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.45 g) was dissolved in dichloromethane (10 mL). To this,N′-hydroxyethanimidamide (0.0758 g),3H-1,2,3-triazolo[4,5-b]pyridin-3-ol (0.0928 g), 4-dimethylaminopyridine(0.00833 g) and triethylamine (0.285 mL) were added. The reactionmixture was allowed to stand still at room temperature overnight.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/9 (V/V)] to obtain the title compound (345 mg (yield:94%)) as a white solid.

15b(2S,5′R)-7-Chloro-3′-methoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 15 (15a): [(Z)-1-aminoethylideneamino](2S,5′R)-7-chloro-1′-methoxy-5′-methyl-3,3′-dioxo-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,6′-cyclohexene]-6-carboxylate(0.345 g) was suspended in toluene (5 mL). The reaction mixture wasstirred at 100° C. for 5 hours. The solvent was distilled away underreduced pressure and the resultant residue was purified by silica gelcolumn chromatography [elution solvent: n-hexane/ethyl acetate=1/1-0/1(V/V)] to obtain the title compound (283 mg (yield: 85%)) as a whitesolid.

15c(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 15 (15b):(2S,5′R)-7-chloro-3′-methoxy-5′-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(2-tetrahydropyran-2-yloxyethoxy)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(0.283 g) was dissolved in ethanol (2 mL). To this, p-toluenesulfonicacid monohydrate (0.0518 g) and water (5 mL) were added. The reactionmixture was stirred at 50° C. for three hours.

The reaction mixture was poured into water and extracted with ethylacetate. The organic layer was washed with water and saturated salineand dried over anhydrous sodium sulfate. The solvent was distilled awayunder reduced pressure and the resultant residue was purified by silicagel column chromatography [elution solvent: methanol/ethylacetate=0/10-1/9 (V/V)] to obtain the title compound (128 mg (yield:54%)) as a white solid.

Example 16(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione16a(2S,5′R)-7-Chloro-4-hydroxy-3′-methoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

The compound of Example 7 (7b):(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(2.3 g) was dissolved in a solvent mixture of toluene (20 mL) and ether(40 mL). To this, magnesium iodide (1.52 g) was added. The reactionmixture was stirred at 80° C. for 5 hours. To the reaction mixture,water was added. The reaction mixture was neutralized with 4 Nhydrochloric acid and extracted with ethyl acetate. The organic layerwas washed with water and saturated saline and dried over anhydroussodium sulfate. The solvent was distilled away under reduced pressureand the resultant residue was purified by silica gel columnchromatography [elution solvent: petroleum ether/ethyl acetate=1/1(V/V)] to obtain the title compound (1.7 g (yield: 64%) as a yellowsolid.

16b(2S,5′R)-7-Chloro-4-(2-hydroxyethoxy)-3′-methoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione

Palladium chloride (0.45 mg) was dissolved in water (2 mL). To this,tetrabutylammonium bromide (10.3 mg) and potassium carbonate (4.42 mg)were added. The reaction mixture was stirred at 60° C. for 15 minutes.To the mixture, the compound of Example 16 (16a):(2S,5′R)-7-chloro-4-hydroxy-3′-methoxy-5′-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dione(50 mg) and oxirane (28.1 mg) were added. The mixture was stirred at 60°C. for 12 hours.

The reaction mixture was poured into water and extracted withdichloromethane. The organic layer was washed with water and saturatedsaline and dried over anhydrous sodium sulfate. The solvent wasdistilled off under reduced pressure. The resultant residue was purifiedby thin layer chromatography [developing solvent: ethyl acetate] toobtain the title compound (16 mg (yield: 29%) as a yellow solid.

In the following tables, the structural formulae of the compoundsdescribed in the Examples and physicochemical data thereof arecollectively shown.

TABLE 2 Ex- am- ple No. Structural formula Physicochemical data 1(1a)

¹H NMR(400 MHz, DMSO-d₆):δ(ppm) = 12.04(1H, brs), 6.28(1H, s), 5.59(1H,s), 3.81(3H, s), 3.63(3H, s), 2.83-2.73(1H, m), 2.68(1H, dd, J = 16.6,13.2 Hz), 2.34(1H, dd, J = 16.6, 4.9 Hz), 0.81(3H, d, J = 6.8 Hz). 1(1b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.15(1H, s), 5.55(2H, s), 4.28(2H, t, J= 4.8 Hz), 4.10-4.04(2H, m), 3.97(3H, s), 3.62(3H, s), 3.04(1H, dd, J =16.6, 13.2 Hz), 2.89-2.80(1H, m), 2.44(1H, dd, J = 16.6, 4.9 Hz),2.10(1H, t, J = 6.4 Hz), 0.97(3H, d, J = 6.4 Hz). MS(ESI) m/z: 383 (M +H)⁺ 2

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.19(1H, s), 5.54(1H, s), 4.31(2H, t, J= 4.4 Hz), 3.95(3H, s), 3.85(2H, t, J = 4.4 Hz), 3.61(3H, s), 3.50(3H,s), 3.04(1H, dd, J = 16.6, 13.7 Hz), 2.89-2.79(1H, m), 2.43(1H, dd, J =16.6, 4.4 Hz), 0.96(3H, d, J = 6.8 Hz). MS(ESI) m/z: 397 (M + H)⁺ 3(3a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) 6.54(1H, s), 5.58(1H, s), 3.99(3H, s),3.65(3H, s), 2.97(1H, dd, J = 16.6, 13.2 Hz), 2.93- 2.81(1H, m),2.48(1H, dd, J = 16.1, 4.4 Hz), 0.98(3H, d, J = 6.8 Hz). 3(3b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.49(1H, d, J = 2.4 Hz), 7.12(1H, s),7.01 (1H, d, J = 2.4 Hz), 5.57(1H, s), 4.02(3H, s), 4.02(3H, s),3.63(3H, s), 3.05(1H, dd, J = 16.6, 13.3 Hz), 2.95- 2.82(1H, m),2.46(1H, dd, J = 16.6, 4.3 Hz), 0.99(3H, d, J = 6.7 Hz). MS(ESI) m/z:403 (M + H)⁺ 4

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.53(1H, d, J = 2.4 Hz), 7.14(1H, s),7.01(1H, d, J = 2.4 Hz), 5.57(1H, s), 4.29(2H, q, J = 7.3 Hz), 4.03(3H,s), 3.64(3H, s), 3.05(1H, dd, J = 16.6, 13.3 Hz), 2.94-2.83(1H, m),2.47(1H, dd, J = 16.6, 4.9 Hz), 1.58(3H, t, J = 7.3 Hz), 1.00(3H, d, J =6.4 Hz). MS(ESI) m/z: 417 (M + H)⁺

TABLE 3 Example No. Structural formula Physicochemical data 5(5a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.48(2H, s), 7.23(1H, s), 5.59(1H, s),4.05(3H, s), 3.65(3H, s), 3.00 (1H, dd, J = 16.1, 13.2 Hz),2.95-2.82(1H, m), 2.50(1H, dd, J = 16.1, 4.4 Hz), 3.00(3H, d, J = 6.8Hz). 5(5b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 9.00(1H, brd, J = 5.4 Hz), 8.59(1H, brd,J = 5.4 Hz), 6.88(1H, s), 5.58(1H, s), 4.00(3H, s), 3.64(3H, s), 2.99(1H, dd, J = 16.6, 13.2 Hz), 2.92-2.83(1H, m), 2.48(1H, dd, J = 16.6,4.4 Hz), 2.17(3H, s,), 0.96(3H, d, J = 6.4 Hz). 5(5c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.23(1H, s), 5.59(1H, s), 4.04(3H, s),3.65(3H, s), 3.05-2.97(1H, m), 2.95-2.86(1H, m), 2.71(3H, s),2.53-2.45(1H, m), 1.00(3H, d, J = 6.3 Hz). MS(ESI) m/z:405 (M + H)⁺.6(6a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.96(1H, s), 5.57(1H, s), 5.03 (2H,brs), 4.00(3H, s), 3.64(3H, s), 3.00(1H, dd, J = 16.6, 13.2 Hz),2.93-2.83(1H, m), 2.48(1 H, dd, J = 16.6, 4.4 Hz), 2.08(3H, s), 0.98(3H,d, J = 6.4 Hz). 6(6b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.24(1H, s), 5.59(1H, s), 4.05(3H, s),3.65(3H, s), 3.00(1H, dd, J = 16.6, 13.2 Hz), 2.96-2.86(1H, m), 2.56(3H,s), 2.50(1H, dd, J = 16.6, 4.4 Hz), 1.00(3H, d, J = 6.6 Hz). MS(ESI)m/z: 405 (M + H)⁺ 7(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.82(1H, s), 5.58(1H, s), 4.00(3H, s),3.63(3H, s), 2.96(1H, dd, J = 16.1, 13.2 Hz), 2.92-2.83(1H, m), 2.49(1H,dd, J = 16.1, 3.9 Hz), 0.97(3H, d, J = 6.4 Hz).

TABLE 4 Example No. Structural formula Physicochemical data 7(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.12(1H, s), 5.57(1H, s), 4.02(3H, s),3.64(3H, s), 3.02(1H, dd, J = 16.6, 13.2 Hz), 2.95-2.85(1H, m), 2.73(3H,s), 2.48(1H, dd, J = 16.6, 4.4 Hz), 1.00(3H, d, J = 6.6 Hz). MS(ESI)m/z:405 (M + H)⁺ 8(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 9.39(1H, brs), 8.83(1H, brs), 6.91 (1H,s), 5.57(1H, s), 4.00(3H, s), 3.64(3H, s), 3.00(1H, dd, J = 16.6, 13.2Hz), 2.93- 2.82(1H, m), 2.47(1H, dd, J = 16.6, 4.4 Hz), 2.43(1H, brs),1.57 (6H, s), 0.97(3H, d, J = 6.4 Hz). 8(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.25 (1H, s), 5.59(1H, s), 4.05(3H, s),3.64(3H, s), 3.01(1H, dd, J = 16.1, 13.2 Hz), 2.97-2.83(1H, m), 2.52(1H,m), 2.49(1H, dd, J = 16.1, 4.4 Hz), 3.81 (6H, s), 1.00(3H, d, J = 6.4Hz). MS(ESI) m/z: 449 (M+ H)⁺ 9(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.89(0.3H, brs), 7.60(0.7H, brs),4.65-4.60(1H, m), 4.35-4.28(1H, m), 3.92-3.81(3H, m), 3.55-3.46(1H, m),1.90-1.72 (2H, m), 1.65-1.52(4H, m), 1.48(2.1H, d, J = 6.8 Hz),1.41(0.9H, d, J = 6.8 Hz). 9(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 9.71(0.2H, d, J = 6.8 Hz), 9.18(0.8H, d,J = 5.9 Hz), 3.94(0.2H, d, J = 6.4 Hz), 8.90(0.8H, d, J = 5.9 Hz),6.93(0.2H, s), 6.92(0.8H, s), 5.58(0.2H, s), 5.57(0.8H, s), 4.81-4.76(0.8H, m), 4.72-4.68(0.2H, m), 4.50-4.41(1H, m), 3.99(3H, s),3.97-3.90(1H, m), 3.68-4.54(4H, m), 3.00(1H, dd, J = 16.2, 13.2 Hz),2.93-2.84(1H, m), 2.48(1H, dd, J = 16.2, 4.4 Hz), 1.96-1.46 (9H, m),0.98(3H, d, J = 6.8 Hz).

TABLE 5 Example No. Structural formula Physicochemical data 9(c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.26(1H, s), 5.58(1H, s), 5.26(0.8H, q,J = 6.4 Hz), 5.17(0.2H, q, J = 6.4 Hz), 4.93-4.89(0.2H, m),4.85-4.80(0.8H, m), 4.04(3H, s), 3.97-3.90(0.8H, m), 3.88-3.81(0.2H, m),3.64(3H, s), 3.63-3.57(0.8H, m), 3.50-3.42(0.2H, m), 3.01(1H, dd, J =16.2, 13.2 Hz), 2.95-2.85(1H, m), 2.49(1H, dd, J = 16.2, 4.4 Hz),1.92-1.80(1H, m), 1.78-1.69(5H, m), 1.68-1.50(3H, m), 1.00(3H, d, J =6.4 Hz). 9(d)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.24(1H, s), 5.58(1H, s), 5.26(1H,quintet J = 6.4 Hz), 4.04(3H, s), 3.64(3H, s), 3.01(2H, dd, J = 16.6,13.7 Hz), 2.95- 2.85(1H, m), 2.55(1H, brs), 2.49(1H, dd, J = 16.6, 4.4Hz), 1.78(3H, d, J = 6.4 Hz), 1.00(3H, d, J = 6.8 Hz). MS(ESI) m/z:435(M+ H)⁺ 10(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.89(0.3H, brs), 7.60(0.7H, brs),4.67-4.60(1H, m), 4.36-4.27(1H, m), 3.96-3.78(3H, m), 3.57-3.46(1H, m),1.91-1.72 (2H, m), 1.65-1.52(4H, m), 1.48(2.1H, d, J = 6.8 Hz),1.42(0.9H, d, J = 6.8 Hz). 10(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 9.72(0.3H, d, J = 6.4 Hz), 9.19(0.7H, d,J = 6.4 Hz), 9.00(0.3H, d, J = 6.4 Hz), 8.96(0.7H, d, J = 6.4 Hz),6.93(0.3H, s), 6.92(0.7H, s), 5.57(1H, s), 4.83-4.76(0.7H, m),4.74-4.67(0.3H, m), 4.52-4.40(2H, m), 4.07-3.88(4H, m), 3.71-3.53(4H,m), 3.06-2.82(2H, m), 2.48(1H, dd, J = 16.6, 4.4 Hz), 1.98-1.45 (9H, m),0.97(3H, d, J = 6.4 Hz). 10(c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.27(1H, s), 5.58(1H, s), 5.30(0.7H, q,J = 6.8 Hz), 5.16(0.3H, q, J = 6.8 Hz), 4.93-4.89(0.3H, m),4.85-4.80(0.7H, m), 4.04(3H, s), 3.97-3.90(0.7H, m), 3.89- 3.81(0.3H,m), 3.64(3H, s), 3.63-3.56(0.7H, m), 3.50-3.41(0.3H, m), 3.05-2.85(2H,m), 2.53-2.45(1H, m), 1.93-1.46(9H, m), 0.99(3H, d, J = 6.8 Hz).

TABLE 6 Example No. Structural formula Physicochemical data 10(d)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.24(1H, s), 5.58(1H, s), 5.26(1H,quintet J = 6.8 Hz), 4.04(3H, s), 3.64(3H, s), 3.01(3H, dd, J = 16.2,13.2 Hz), 2.95-2.85(1H, m), 2.56(1H, brs), 2.49(1H, dd, J = 16.6, 4.4Hz), 1.78(3H, d, J = 6.8 Hz), 1.00(3H, d, J = 6.8 Hz). MS(ESI) m/z: 435(M + H)⁺ 11(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.28 (1H, s), 5.61(1H, s), 4.04(1H, s),3.68(3H, s), 3.05-2.87(2H, m), 2.59-2.52(1H, m), 1.80(5H, s), 1.02(3H,d, J = 6.4 Hz). 11(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.22(1H, s), 5.57(1H, s), 4.31-4.23(2H,m), 3.64(3H, s), 3.02(1H, dd, J = 16.6, 13.7 Hz), 2.95-2.85(1H, m),2.56-2.42(2H, m), 1.81 (6H, s), 1.54(3H, t, J = 6.8 Hz), 1.00(3H, d, J =6.4 Hz). MS(ESI) m/z: 463 (M + H)⁺ 12

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.22(1H, s), 5.57(1H, s), 5.31-5.21(1H,m), 4.32-4.22(2H, m), 3.64(3H, s), 3.03(1H, dd, J = 16.6, 13.2 Hz),2.96-2.85(1H, m), 2.52-2.44(2H, m), 1.78(3H, d, J = 6.4 Hz), 1.54(3H, t,J = 6.3 Hz), 1.00(3H, d, J = 6.4 Hz). MS(ESI) m/z: 449 (M+ H)⁺ 13(13a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 4.93-4.86(1H, m), 4.65(1H, q, J = 6.8Hz), 3.82-3.72(1H, m), 3.60-3.52(1H, m), 1.90-1.71(2H, m), 1.69-1.49(7H,m). ¹H NMR(400 MHz, CDCl₃):δ(ppm) = 4.81-4.77(1H, m), 4.39(1H, q, J =6.8 Hz), 3.97(1H, td, J = 11.7, 2.9 Hz), 3.67-3.60(1H, m), 1.90-1.52(9H,m).

TABLE 7 Example No. Structural formula Physicochemical data 13(13b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.70(1H, brs), 4.70 (2H, brs),4.63-4.58(1H, m), 4.36(1H, q, J = 6.8 Hz), 3.93-3.83(1H, m),3.56-3.48(1H, m), 1.90-1.78(1H, m), 1.75-1.66(1H, m), 1.63-1.49(4H, m),1.44(3H, d, J = 6.8 Hz). 13(13c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.97(1H, s), 5.57(1H, s), 5.21(2H, brs),4.78-4.61(2H, m), 4.00(3H, s), 3.94-3.85(1H, m), 3.63(3H, s),3.59-3.51(1H, m), 3.00) 1H, dd, J = 16.6, 13.7 Hz), 2.93-2.82(1H, m),2.48(1H, dd, J = 16.6, 4.4 Hz), 1.90-1.79(1H, m), 1.78-1.69(1H, m),3.63-1.49(7H, m), 0.98(3H, d, J = 6.8 Hz). 13(13d)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.27(1H, s), 5.58(1H, s), 5.23(1H, q, J= 6.8 Hz), 4.79-4.70(1H, m), 4.05(3H, s), 3.99-3.92(1H, m), 3.63(3H, s),3.62-3.56) 1H, m), 3.00(3H, dd, J = 16.6,13.7 Hz), 2.95-2.85(1H, m),2.49(1H, dd, J = 16.6, 4.4 Hz), 1.94-1.83(1H, m), 1.78-1.50(8H, m),0.99(3H, d, J = 6.8 Hz). 13(13e)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.25(1H, s), 5.58(1H, s), 5.17(1H,quintet, J = 6.8 Hz), 4.06(3H, s), 3.64(3H, s), 3.00)1H, dd, J = 36.6,13.2 Hz), 2.96-2.85(1H, m), 2.50(1H, dd, J = 16.6, 4.4 Hz),2.48-2.43(1H, m), 1.73(3H, d, J = 6.8 Hz), 1.00(3H, d, J = 6.4 Hz).MS(ESI) m/z:435 (M+ H)⁺. 14(14a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.76(1H, brs), 6.19(1H, s), 5.57(1H, s),3.98(3H, s), 3.66(3H, s), 3.00-2.82(2H, m), 2.49(1H, dd, J = 16.6, 4.4Hz), 0.99(3H, d, J = 6.4 Hz). 14(14b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.26(1H, s), 5.54(1H, s), 4.75-4.69(1H,m), 4.40-4.29(2H, m), 4.15-4.08(1H, m), 4.00(3H, s), 3.96-3.85(2H, m),3.62(3H, s), 3.57-3.50(1H, m), 3.03(1H, dd, J = 16.6, 13.2 Hz),2.89-2.79(1H, m), 2.46- 2.39(1H, m), 1.88-1.68(2H, m), 3.62-1.45(4H, m),0.96(3H, d, J = 6.8 Hz).

TABLE 8 Example No. Structural formula Physicochemical data 14(14c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.30(1H, s), 5.54(1H, s), 4.78-4.71(1H,m), 4.30-4.21(2H, m), 4.17-4.04(1H, m), 3.95-3.84(2H, m), 3.63(3H, s),3.57-3.50(1H, m), 3.04(1H, dd, J = 16.6, 13.2 Hz), 2.88-2.77(1H, m),2.46-2.39(1H, m), 1.85-1.47(6H, m), 0.97(3H, d, J = 6.8 Hz). 14(14d)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 6.67(1H, s), 5.57(1H, s), 4.75-4.70(1H,m), 4.37-4.28(2H, m), 4.15-4.07(1H, m), 3.93-3.84(2H, m), 3.65(3H, s),3.57-3.51(1H, m), 3.01- 2.93(1H, m), 2.92-2.81(1H, m), 2.52-2.44(1H, m),l.84-1.68(2H, m), 1.65-1.46(4H, m), 0.98(3H, d, J = 6.8 Hz). 14(14e)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.47(2H, s), 7.32(1H, s), 5.58(1H, s),4.76-4.72(1H, m), 4.44-4.36(2H, m), 4.17-4.07(1H, m), 3.96-3.84(2H, m),3.65(3H, s), 3.57-3.43(1H, m), 3.04-2.96(1H, m), 2.95-2.86(1H, m),2.52-2.44(1H, m), 1.83-1.67(2H, m), 1.64-1.44(4H, m), 0.99(3H, d, J =6.8 Hz). 14(14f)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 8.97-8.86(1H, m), 8.45-8.32(1H, m),6.96(1H, s), 5.56(1H, s), 4.77- 4.70(1H, m), 4.40-4.29(2H, m),4.14-4.05(1H, m), 3.94-3.84(2H, m), 3.64(3H, s), 3.57-3.50(1H, m),3.00(1H, dd, J = 16.1, 13.6 Hz), 2.93-2.82(1H, m), 2.47(1H, dd, J =16.6, 3.9 Hz), 2.16(3H, s), 1.87- 1.67(2H, m), 1.64-1.46(4H, m),0.97(3H, d, J = 6.8 Hz).

TABLE 9 Example No. Structural formula Physicochemical data 14(14g)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.29(1H, s), 5.57(1H, s), 4.78-4.72(1H,m), 4.43-4.33(2H, m), 4.16-4.08(1H, m), 3.95-3.85(2H, m), 3.64(3H, s),3.58-3.51(1H, m), 3.01(1H, dd, J = 16.1, 13.2 Hz), 2.95-2.85(1H, m),2.70(3H, s), 2.52- 2.44(1H, m), 1.85-1.68(2H, m), 1.64-1.47(4H, m),0.99(3H, d, 6.4 Hz). 14(14h)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.25(1H, s), 5.58(1H, s), 4.33-4.23(2H,m), 4.10-3.96(2H, m), 3.65(3H, s), 3.04-2.85(2H, m), 2.71(3H, s),2.60-2.46(2H, m), 1.00(3H, d, J = 6.8 Hz). MS(ESI) m/z: 435(M+ H)⁺15(15a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.04(1H, s), 5.56(1H, s), 4.78-4.72(1H,m), 4.40-4.29(2H, m), 4.14-4.06(1H, m), 3.93-3.84(2H, m), 3.64(3H, s),3.57-3.50(1H, m), 3.00(1H, dd, J = 16.5, 13.2 Hz), 2.93-2.82(1H, m),2.47(1H, dd, J = 16.6, 3.2 Hz), 2.08(3H, s), 1.85-1.67(2H, m),1.64-1.47(4H, m), 0.97(3H, d, J = 6.4 Hz). 15(15b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.33(1H, s), 5.57(1H, s), 4.78-4.72(1H,m), 4.45-4.34(2H, m), 4.16-4.08(1H, m), 3.95-3.83(2H, m), 3.64(3H, s),3.58-3.51(1H, m), 3.00(1H, dd, J = 16.1, 13.2 Hz), 2.95-2.86(1H, m),2.54(3H, s), 2.48(1H, dd, J = 16.1, 3.2 Hz), 1.85-1.68(2H, m),1.64-1.47(4H, m), 0.99(3H, d, J = 6.4 Hz). 15(15c)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.25(1H, s), 5.58(1H, s), 4.33-4.25(2H,m), 4.09-3.98(2H, m), 3.65(3H, s), 2.99(1H, dd, J = 16.1, 13.2 Hz),2.96- 2.87(1H, m), 2.55(3H, s), 2.54 (1H, d, J = 6.4 Hz), 2.50(1H, dd, J= 16.1, 3.9 Hz), 1.00(3H, d, J = 6.4 Hz). MS(ESI) m/z: 435 (M + H)⁺

TABLE 10 Example No. Structural formula Physicochemical data 16(a)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.72(1H, brs), 7.16 (1H, s), 5.60(1H,s), 3.68(3H, s), 3.10-2.85(2H, m), 2.72(3H, s), 2.59-2.43(1H, m),1.01(3H, d, J = 6.4 Hz). 16(b)

¹H NMR(400 MHz, CDCl₃):δ(ppm) = 7.15(1H, s), 5.58(1H, s), 4.38-4.23(2H,m), 4.15-3.92(2H, m), 3.66(3H, s), 3.08- 2.85(2H, m), 2.74(3H, s),2.49(1H, dd, J = 16.1, 3.9 Hz), 1.00(3H, d, J = 6.4 Hz). MS(ESI) m/z:435 (M + H)⁺

1-16. (canceled)
 17. The compound(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dioneor a pharmaceutically acceptable salt thereof.
 18. A pharmaceuticalcomposition comprising the compound or a pharmaceutically acceptablesalt thereof of claim 17 and a pharmaceutically acceptable carrier. 19.A method of treating an inflammatory disease in a subject in needthereof, comprising administering to the subject an effective amount ofthe compound(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dioneor a pharmaceutically acceptable salt thereof.
 20. The method accordingto claim 19, wherein the inflammatory disease is a disease selected fromthe group consisting of rheumatoid arthritis, systemic lupuserythematosus, scleroderma, bronchial asthma, asthmatic bronchitis,diffuse interstitial pneumonia, chronic obstructive pulmonary disease,ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis,fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis,primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholicsteatohepatitis, cirrhosis, peripheral neuritis, ankylosing spondylitis,eczema (acute, subacute, chronic), contact dermatitis, sunlight(ultraviolet light) dermatitis, radiation dermatitis, atopic dermatitis,seborrheic dermatitis, psoriasis vulgaris, arthropathic psoriasis,psoriatic erythroderma, pustular psoriasis, lichen planus, erythema,rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acnevulgaris, pressure sore, wound, burn, conjunctivitis, keratitis,scleritis, acute/chronic otitis media, perennial allergic rhinitis, hayfever, sinusitis, laryngitis, esophagitis, refractory stomatitis,glossitis, acute/chronic salivary gland inflammation, angular cheilitis,cheilitis, Behcet's disease, multiple sclerosis, Type I diabetes, TypeII diabetes, atherosclerosis, pancreatitis and chronic heart failure.21. The method according to claim 19, wherein the inflammatory diseaseis a disease selected from the group consisting of rheumatoid arthritis,systemic lupus erythematosus, bronchial asthma, acute hepatitis,autoimmune hepatitis, primary biliary cirrhosis, primary sclerosingcholangitis, alcoholic hepatitis, nonalcoholic steatohepatitis,ankylosing spondylitis, contact dermatitis, sunlight (UV) dermatitis,atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris,arthropathic psoriasis, psoriatic erythroderma, pustular psoriasis,lichen planus, erythema, rosacea, alopecia areata, pemphigus,erythroderma, acne vulgaris, pressure sore, wound, burn, sinusitis,laryngitis, esophagitis, refractory stomatitis, glossitis, acute/chronicsalivary gland inflammation, angular cheilitis, cheilitis and Behcet'sdisease.
 22. The method according to claim 19, wherein the inflammatorydisease is a disease selected from the group consisting of rheumatoidarthritis, systemic lupus erythematosus, autoimmune hepatitis, alcoholichepatitis, nonalcoholic steatohepatitis, ankylosing spondylitis, atopicdermatitis, psoriasis vulgaris, arthropathic psoriasis, psoriaticerythroderma, pustular psoriasis, lichen planus, pressure sore, wound,refractory stomatitis, glossitis and Behcet's disease.
 23. A method oftreating an inflammatory disease in a subject in need thereof,comprising administering to the subject an effective amount of apharmaceutical composition comprising the compound(2S,5′R)-7-chloro-3′,4-dimethoxy-5′-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4′-cyclohex-2-ene]-1′,3-dioneor a pharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable carrier.
 24. The method according to claim 23, wherein theinflammatory disease is a disease selected from the group consisting ofrheumatoid arthritis, systemic lupus erythematosus, scleroderma,bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia,chronic obstructive pulmonary disease, ulcerative colitis, Crohn'sdisease, acute hepatitis, chronic hepatitis, fulminant hepatitis,autoimmune hepatitis, primary biliary cirrhosis, primary sclerosingcholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis,cirrhosis, peripheral neuritis, ankylosing spondylitis, eczema (acute,subacute, chronic), contact dermatitis, sunlight (ultraviolet light)dermatitis, radiation dermatitis, atopic dermatitis, seborrheicdermatitis, psoriasis vulgaris, arthropathic psoriasis, psoriaticerythroderma, pustular psoriasis, lichen planus, erythema, rosacea,urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris,pressure sore, wound, burn, conjunctivitis, keratitis, scleritis,acute/chronic otitis media, perennial allergic rhinitis, hay fever,sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis,acute/chronic salivary gland inflammation, angular cheilitis, cheilitis,Behcet's disease, multiple sclerosis, Type I diabetes, Type II diabetes,atherosclerosis, pancreatitis and chronic heart failure.
 25. The methodaccording to claim 23, wherein the inflammatory disease is a diseaseselected from the group consisting of rheumatoid arthritis, systemiclupus erythematosus, bronchial asthma, acute hepatitis, autoimmunehepatitis, primary biliary cirrhosis, primary sclerosing cholangitis,alcoholic hepatitis, nonalcoholic steatohepatitis, ankylosingspondylitis, contact dermatitis, sunlight (UV) dermatitis, atopicdermatitis, seborrheic dermatitis, psoriasis vulgaris, arthropathicpsoriasis, psoriatic erythroderma, pustular psoriasis, lichen planus,erythema, rosacea, alopecia areata, pemphigus, erythroderma, acnevulgaris, pressure sore, wound, burn, sinusitis, laryngitis,esophagitis, refractory stomatitis, glossitis, acute/chronic salivarygland inflammation, angular cheilitis, cheilitis and Behcet's disease.26. The method according to claim 23, wherein the inflammatory diseaseis a disease selected from the group consisting of rheumatoid arthritis,systemic lupus erythematosus, autoimmune hepatitis, alcoholic hepatitis,nonalcoholic steatohepatitis, ankylosing spondylitis, atopic dermatitis,psoriasis vulgaris, arthropathic psoriasis, psoriatic erythroderma,pustular psoriasis, lichen planus, pressure sore, wound, refractorystomatitis, glossitis and Behcet's disease.